Generic Name:
ospemifene
Project Status:
Complete
Therapeutic Area:
Dyspareunia, vaginal dryness
Manufacturer:
Duchesnay Inc.
Brand Name:
Osphena
Project Line:
Reimbursement Review
Project Number:
SR0709-000
NOC Status at Filing:
Post NOC
Details
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Osphena is indicated in postmenopausal women for the treatment of moderate to severe dyspareunia and/or vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Osphena is indicated in postmenopausal women for the treatment of moderate to severe dyspareunia and/or vaginal dryness, symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.